OPCML and cholangiocarcinoma: Similarly, promoter methylation of OPCML and HOXD9 assessed in serum cell free DNA using methylation-sensitive high-resolution melting, was detected with a sensitivity of 62.50% with specificity of 100%, thus could serve as a non-invasive differential biomarker to prevent misdiagnosis of cholangiocarcinoma (CCA) and other biliary diseases (Wasenang et al., 2019).